

Federica Papaccio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2539505/publications.pdf>

Version: 2024-02-01

26
papers

1,895
citations

394421
19
h-index

610901
24
g-index

26
all docs

26
docs citations

26
times ranked

4038
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. ESMO Open, 2020, 5, e000847.	4.5	21
2	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Journal of Clinical Medicine, 2020, 9, 3049.	2.4	12
3	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 3611.	3.7	30
4	Circulating cancer stem cells: an interesting niche to explore. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 253-258.	0.8	4
5	Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. Journal of Experimental and Clinical Cancer Research, 2019, 38, 160.	8.6	59
6	Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. Scientific Reports, 2019, 9, 4986.	3.3	15
7	In the literature: August 2018. ESMO Open, 2019, 4, e000563.	4.5	0
8	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. ESMO Open, 2019, 4, e000536.	4.5	26
9	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. Cancer Treatment Reviews, 2018, 63, 156-171.	7.7	34
10	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 3595.	4.1	78
11	Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer. ESMO Open, 2018, 3, e000425.	4.5	39
12	HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 296.	8.6	49
13	A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. Cell Death and Disease, 2018, 9, 572.	6.3	138
14	Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development. Stem Cells Translational Medicine, 2017, 6, 2115-2125.	3.3	232
15	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open, 2017, 2, e000132.	4.5	61
16	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. Journal of Hematology and Oncology, 2017, 10, 161.	17.0	29
17	Implication of the Hedgehog pathway in hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 4330.	3.3	54
18	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget, 2016, 7, 4265-4278.	1.8	58

#	ARTICLE	IF	CITATIONS
19	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. Journal of Thoracic Oncology, 2015, 10, 1133-1141.	1.1	212
20	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. Clinical Cancer Research, 2015, 21, 4686-4697.	7.0	103
21	A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Nonâ€“Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. Clinical Lung Cancer, 2015, 16, 57-59.	2.6	16
22	Stemness markers of osteosarcoma. , 2015, , 205-211.		1
23	Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget, 2015, 6, 71-84.	1.8	66
24	Role of HGFâ€“MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines, 2014, 2, 345-358.	3.2	30
25	Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB Journal, 2013, 27, 13-24.	0.5	338
26	Human primary bone sarcomas contain CD133 ⁺ cancer stem cells displaying high tumorigenicity <i>in vivo</i> . FASEB Journal, 2011, 25, 2022-2030.	0.5	190